Inovio Pharmaceuticals, Inc. (INO)
After hours:
| Previous close | 5.41 |
| Open | 5.39 |
| Bid | 5.73 x 100 |
| Ask | 5.77 x 300 |
| Day's range | 5.39 - 5.76 |
| 52-week range | 3.84 - 14.75 |
| Volume | |
| Avg. volume | 319,573 |
| Market cap | 149.295M |
| Beta (5Y monthly) | 0.82 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -5.07 |
| Earnings date | 07 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.75 |
ZacksInovio (INO) Surges 6.8%: Is This an Indication of Further Gains?
Inovio (INO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
PR NewswireINOVIO Reports Inducement Grants Under Inducement Plan
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made equity grants to certain employees under its 2022 Inducement Plan (the "Inducement Plan").
- PR Newswire
INOVIO to Present at Upcoming Scientific Conferences
INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it will present at the following scientific conferences:
